相关实验视频
Updated: Jan 17, 2026

13:25
Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
Published on: May 15, 2021
6.5K
罗克萨杜沙特通过调节脂肪酸氧化和线粒体功能来缓解西斯普拉丁诱导的急性损伤
Xialin Li1, Yan Hu1, Jinqing Li1
1Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Renal failure
|September 19, 2025
概括
低氧诱导因子稳定剂Roxadustat通过改善脂肪酸氧化和减少小鼠和细胞的线粒体损伤,保护免受西斯普拉丁诱导的急性损伤 (AKI).
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 西斯普拉丁是一种广泛使用的化疗剂,可导致严重的急性损伤 (AKI).
- 低氧诱导因子 (HIF) 稳定剂代表了AKI的潜在治疗策略.
- 罗克萨杜沙特是一种小分子HIF稳定剂,具有潜在的保护性质.
研究的目的:
- 为了研究roxadustat对西斯普拉丁诱导的AKI的保护作用.
- 阐明roxadustat在AKI中的作用的基本机制.
- 为了评估roxadustat的有效性,无论是在体内*还是体外*.
主要方法:
- 建立了基斯普拉丁诱导的AKI的小鼠模型,并用roxadustat进行预治疗.
- 治疗HK-2细胞时使用西斯普拉丁和罗克萨杜沙特 *in vitro*.
- 评估了功能标记物 (Scr,BUN),形态,亡标记物 (Bax,分裂的caspase 3),脂肪酸氧化 (FAO) 和线粒体完整性.
主要成果:
- 在西斯普拉丁诱导的AKI小鼠中,Roxadustat预治疗显著改善了功能,并减轻了病变.
- 在体内和体外模型中,Roxadustat降低了亡标志物,改善了脂肪酸氧化 (FAO) 和线粒体损伤.
- 罗克萨杜沙特治疗导致KIM-1和NGAL水平降低,并部分恢复了线粒体融合蛋白.
结论:
- 罗沙沙斯塔特显示出显著的脏保护作用,防止西斯普拉丁诱导的AKI.
- 保护机制包括改善FAO缺陷和抑制线粒体损伤.
- 罗沙杜沙特作为预防或治疗化疗诱导的AKI的治疗剂具有前景.
相关概念视频
Acute Kidney Injury IV: Diagnostic Studies and Prevention
271
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
271
Renal Failure: Dose Adjustments
438
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
438
Renal Drug Excretion: Tubular Secretion
794
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
794
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
209
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
209
Acute Kidney Injury V: Interprofessional Care
297
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
297
Electron Transport Chain: Complex I and II
18.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.5K

